Anal squamous cell carcinoma: An evolution in disease and management

World Journal of Gastroenterology

Volumn 20, Issue 36, 2014, Pages 13052-13059

  Osborne, Marc C ^a   Maykel, Justin ^b   Johnson, Eric K ^c   Steele, Scott R ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

^c MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

Anal cancer; Anal intraepithelial neoplasia; Anal neoplasm; Cancer screening; Chemoradiation therapy; Drug therapy; Nigro protocol; Radiotherapy; Squamous cell cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ANAL SQUAMOUS CELL CARCINOMA; ANUS CARCINOMA; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; EARLY DIAGNOSIS; PATHOLOGY; PREDICTIVE VALUE; SECONDARY; TUMOR RECURRENCE;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84928403593     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i36.13052     Document Type: Article

References (50)

1. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17 : 354-356 [PMID: 4830803 DOI: 10.1007/ BF02586980]
2. Anal Cancer [Internet]. U.S. Natl. Institutes Heal. Available from: URL: http://www.cancer.gov/cancertopics/types/anal. Accessed on Feb 3, 2014
3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 Suppl 3: S3/11-S3/25 [PMID: 16949997]
4. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts R, Berry JM, Jay N, Darragh TM. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIVpositive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 314-319 [PMID: 9525431 DOI: 10.1097/00042560-199804010-00004]
5. Devaraj B, Cosman BC. Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum 2006; 49: 36-40 [PMID: 16283561 DOI: 10.1007/s10350-005- 0229-z]
6. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males-Advisory Committee on Immunization Practices (ACIP), 2011 MMWR. December 23, 2011; 60: 1705-1708. Available from: URL: http://www. cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm. Accessed on Feb 26, 2014)
7. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-1585 [PMID: 22029979 DOI: 10.1056/NEJMoa1010971]
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Anal Carcinoma Version 2. 2014. Available from: URL: http://www.nccn.org/professionals/physician-gls/ pdf/anal.pdf. Accessed on Feb 26, 2014
9. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 2002; 45: 453-458 [PMID: 12006924 DOI: 10.1007/s10350-004-6219-8]
10. Arain S, Walts AE, Thomas P, Bose S. The Anal Pap Smear: Cytomorphology of squamous intraepithelial lesions. Cytojournal 2005; 2 : 4 [PMID: 15715910 DOI: 10.1186/1742-6413-2-4]
11. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 415-422 [PMID: 9170415 DOI: 10.1097/00042560-199704150-00004]
12. Fox PA, Seet JE, Stebbing J, Francis N, Barton SE, Strauss S, Allen-Mersh TG, Gazzard BG, Bower M. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Infect 2005; 81: 142-146 [PMID: 15800092 DOI: 10.1136/sti.2003.008318]
13. Chin-Hong PV, Berry JM, Cheng SC, Catania JA, Da Costa M, Darragh TM, Fishman F, Jay N, Pollack LM, Palefsky JM. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med 2008; 149: 300-306 [PMID: 18765699 DOI: 10.7326/0003-4819-149-5-200809020-00004]
14. Wieland U, Brockmeyer NH, Weissenborn SJ, Hochdorfer B, Stücker M, Swoboda J, Altmeyer P, Pfister H, Kreuter A. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006; 142: 1438-1444 [PMID: 17116834 DOI: 10.1001/archderm.142.11.1438]
15. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P, Swoboda J, Pfister H, Wieland U. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol 2008; 128: 2078-2083 [PMID: 18273049 DOI: 10.1038/jid.2008.24]
16. Richel O, Wieland U, de Vries HJ, Brockmeyer NH, van Noesel C, Potthoff A, Prins JM, Kreuter A. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol 2010; 163: 1301-1307 [PMID: 20716208 DOI: 10.1111/ j.1365-2133.2010.09982.x]
17. Kruijt B, van der Snoek EM, Sterenborg HJ, Amelink A, Robinson DJ. A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia. Photodiagnosis Photodyn Ther 2010; 7: 3-9 [PMID: 20230986 DOI: 10.1016/j.pdpdt.2010.01.006]
18. Margenthaler JA, Dietz DW, Mutch MG, Birnbaum EH, Kodner IJ, Fleshman JW. Outcomes, risk of other malignancies, and need for formal mapping procedures in patients with perianal Bowen's disease. Dis Colon Rectum 2004; 47: 1655-160; discussion 1655-160; [PMID: 15540295]
19. Chang GJ, Welton ML. Human papillomavirus, condylomata acuminata, and anal neoplasia. Clin Colon Rectal Surg 2004; 17: 221-230 [PMID: 20011263 DOI: 10.1055/s-2004-836942]
20. Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg 2007; 33 : 427-31; discussion 431-2 [PMID: 17430376 DOI: 10.1111/j.1524-4725.2007.33089.x]
21. Graham BD, Jetmore AB, Foote JE, Arnold LK. Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Dis Colon Rectum 2005; 48: 444-450 [PMID: 15747068 DOI: 10.1007/s10350-004-0901-8]
22. Brown SR, Skinner P, Tidy J, Smith JH, Sharp F, Hosie KB. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen's disease). Br J Surg 1999; 86: 1063-1066 [PMID: 10460644 DOI: 10.1046/j.1365-2168.1999.01184.x]
23. Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC. Perianal Bowen's disease: a clinicopathologic study of 47 patients. Dis Colon Rectum 1997; 40: 1286-1293 [PMID: 9369101 DOI: 10.1007/BF02050810]
24. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 2005; 48: 1042-1054 [PMID: 15868241 DOI: 10.1007/s10350-004-0889-0]
25. Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 2006; 76: 715-717 [PMID: 16916390 DOI: 10.1111/ j.1445-2197.2006.03837.x]
26. Steele SR, Varma MG, Melton GB, Ross HM, Rafferty JF, Buie WD. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2012; 55: 735-749 [PMID: 22706125 DOI: 10.1097/DCR.0b013e318255815e]
27. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348: 1049-1054 [PMID: 8874455 DOI: 10.1016/S0140-6736(96)03409-5]
28. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049 [PMID: 9164216]
29. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008; 299 : 1914-1921 [PMID: 18430910 DOI: 10.1001/jama.299.16.1914]
30. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 2013; 14: 516-524 [PMID: 23578724 DOI: 10.1016/S1470-2045(13)70086-X]
31. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010; 28 : 5061-5066 [PMID: 20956625 DOI: 10.1200/ JCO.2010.29.1351]
32. Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, Zaccariotto A, Bénézery K, Franc¸ois E, Salem N, Ellis S, Azria D, Gerard JP. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys 2011; 80: 712-720 [PMID: 20619552 DOI: 10.1016/ j.ijrobp.2010.02.055]
33. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R. Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol 2008; 87 : 367-375 [PMID: 18501453 DOI: 10.1016/j.radonc.2008.05.001]
34. Glynne-Jones R, Sebag-Montefiore D, Adams R, McDonald A, Gollins S, James R, Northover JM, Meadows HM, Jitlal M. "Mind the gap" - the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). Int J Radiat Oncol Biol Phys 2011; 81 : 1488-1494 [PMID: 20934265 DOI: 10.1016/ j.ijrobp.2010.07.1995]
35. Janssen S, Meier zu Eissen J, Kolbert G, Bremer M, Karstens JH, Meyer A. Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome. Int J Colorectal Dis 2009; 24 : 1421-1428 [PMID: 19649642 DOI: 10.1007/s00384-009-0775-2]
36. Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007; 25: 4581-4586 [PMID: 17925552 DOI: 10.1200/JCO.2007.12.0170]
37. Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010; 78: 1413-1419 [PMID: 20231064 DOI: 10.1016/j.ijrobp.2009.09.046]
38. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008; 51: 147-153 [PMID: 18180997 DOI: 10.1007/s10350-007-9125-z]
39. Papaconstantinou HT, Bullard KM, Rothenberger DA, Madoff RD. Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Colorectal Dis 2006; 8 : 124-129 [PMID: 16412072 DOI: 10.1111/j.1463-1318.2005.00911.x]
40. Glynne-Jones R . James R, Meadows H, Begum R, Cunningham D, Northover J, Ledermann JA, Beare S, Kadalayil L, Sebag-Montefiore D. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. 2012 ASCO Annual Meeting Abstracts. J Clin Oncol, Vol 30, No 15-suppl (May 20 Supplement), 2012: 4004. Available from: URL: http://meeting.ascopubs.org/cgi/content/abstract/30/15-suppl/4004
41. van der Wal BC, Cleffken BI, Gulec B, Kaufman HS, Choti MA. Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. J Gastrointest Surg 2001; 5: 383-387 [PMID: 11985979]
42. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, Bardou VJ, Delpero JR. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum 2005; 48: 16-22 [PMID: 15690652 DOI: 10.1007/s10350-004-0746-1]
43. Chessin DB, Hartley J, Cohen AM, Mazumdar M, Cordeiro P, Disa J, Mehrara B, Minsky BD, Paty P, Weiser M, Wong WD, Guillem JG. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol 2005; 12 : 104-110 [PMID: 15827789 DOI: 10.1245/ASO.2005.03.100]
44. Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer 1999; 86: 861-865 [PMID: 10572237]
45. Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, Alcindor T, Vuong T. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer 2012; 107: 1864-1868 [PMID: 23093229 DOI: 10.1038/ bjc.2012.479]
46. Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Paris E, Juzyna B, Ezra P, Azria D. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 2013; 24: 2834-2838 [PMID: 24026540 DOI: 10.1093/annonc/mdt368]
47. Olivatto LO, Vieira FM, Pereira BV, Victorino AP, Bezerra M, Araujo CM, Erlich F, Faroni L, Castro L, Lusis EC, Marins A, Ferreira CG. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 2013; 119: 2973-2980 [PMID: 23674135 DOI: 10.1002/cncr.28045]
48. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008; 87: 383-390 [DOI: 10.1016/ j.radonc.2008.04.011]
49. Dasgupta T, Rothenstein D, Chou JF, Zhang Z, Wright JL, Saltz LB, Temple LK, Paty PB, Weiser MR, Guillem JG, Nash GM, Goodman KA. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol 2013; 107 : 189-194 [PMID: 23692961 DOI: 10.1016/ j.radonc.2013.03.012]
50. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS. Dose-painted in-tensity- modulated radiation therapy for anal cancer: a multiinstitutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012; 82: 153-158 [PMID: 21095071 DOI: 10.1016/j.ijrobp.2010.09.030]